AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. Valued at a market cap of ...

This was the stock's second consecutive day of gains.

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.02% to 5,985.38 ...

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...